Study of Changes in Gut Microbiota After Transcatheter Aortic Valve Implantation TAVI in Patients with Severe Aortic Valve Stenosis

What this Trial Is About

This research aims to explore how transcatheter aortic valve implantation TAVI affects the gut microbiota in patients with severe aortic valve stenosis. The study investigates whether improved heart function after TAVI can positively change gut bacteria by enhancing blood flow to the intestines and reducing congestion. The trial will enroll 40 patients undergoing TAVI to analyze stool and blood samples before and after the procedure. Participants will undergo two main study phases before TAVI and three to four months after TAVI. During these phases, stool samples will be collected for 16S rRNA sequencing to assess gut microbiota changes, and blood samples will measure markers like TMAO and other related health indicators. Dietary questionnaires will also be completed at each timepoint to consider diets influence on gut bacteria. Participants will be assessed at baseline 1 month to 1 day before TAVI and followed up 3 to 4 months after the procedure. Data collected include medical history, echocardiography, blood tests, stool samples, and dietary information. The studys main outcome is the change in gut microbiota composition after TAVI, with secondary outcomes examining serum TMAO levels and their relationship to heart valve severity and function. Safety and eligibility are monitored throughout, with follow-up adjusted if antibiotics are used.

Impact of Transcatheter Aortic Valve Implantation (TAVI) on the Gut Microbiota in Patients With Aortic Valve Stenosis